Company overview
Prota Therapeutics is a late clinical-stage Australian biotech company developing novel oral immunotherapies for food allergies, with lead product PRT120 targeting peanut allergy remission. PRT120, a high-dose peanut oral immunotherapy, has shown efficacy in inducing sustained unresponsiveness in Phase 2b trials, enabling patients to eat peanuts freely without ongoing treatment. The company, founded in 2016 and headquartered in Melbourne, holds IP from Murdoch Children’s Research Institute and is preparing for Phase 3 trials.
Prota Therapeutics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include peanut allergy treatment, oral immunotherapy, prt120, food allergy remission, allergen immunotherapy.
Structured facts
- Website
- https://protatherapeutics.com
- Markets served
- United States & Americas
- Keywords
- peanut allergy treatment, oral immunotherapy, prt120, food allergy remission, allergen immunotherapy
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Prota Therapeutics' lead product and its development stage?
- PRT120 is a proprietary high-dose peanut oral immunotherapy in late clinical-stage development, Phase 3-ready, shown to induce remission in 51% of patients in Phase 2b trials with sustained benefits at 2-year follow-up.
- What clinical outcomes has PRT120 demonstrated?
- PRT120 achieves remission of peanut allergy, allowing free peanut consumption without reactions even after weeks or months off treatment, with significant improvements in health-related quality of life compared to placebo or desensitization.
- Where is Prota Therapeutics based and what is their focus?
- Headquartered in Melbourne, Australia, Prota focuses on oral immunotherapies for food allergies, particularly peanut allergy, originating from technology developed at Murdoch Children’s Research Institute.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
